URGP.OB: Summary for URIGEN PHARMACEUTCLS - Yahoo! Canada Finance

	Sign In [New User? Sign Up]	Finance Home \|Help

Wednesday, November 25, 2009, 6:44am EST - Canadian Markets open in 2 hours and 46 minutes.

To create a watchlist or portfolio of shares, Sign-in or Register

Urigen Pharmaceuticals, Inc. (URGP.OB)

On Nov 24: 0.0706 USD 0.00 (0.00%)

MORE ON URGP.OB

Quotes

Summary

Charts

News & Info

Company

Analyst Coverage

Ownership

Financials

URIGEN PHARMACEUTCLS (OTC BB:URGP.OB) Delayed quote data

Last Trade:	0.0706 USD
Trade Time:	Nov 24
Change:	0.00 (0.00%)
Prev Close:	0.0706
Open:	N/A
Bid:	N/A
Ask:	N/A
1y Target Est:	9.00

Day's Range:	N/A - N/A
52wk Range:	0.02 - 0.19
Volume:	0
Avg Vol (3m):	288,756
Market Cap:	5.19M
P/E (ttm):	N/A
EPS (ttm):	-0.035
Div & Yield:	N/A (N/A%)

1d 5d 3m 6m 1y 2y 5y max

Add URGP.OB to Portfolio

Download Data

HEADLINES

•	URIGEN PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report
	EDGAR Online (Mon, Nov 16)

•	Company Profile for Urigen Pharmaceuticals, Inc.
	Business Wire (Fri, Oct 30)

•	URIGEN PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Regulation FD Disclosure
	EDGAR Online (Thu, Oct 29)

•	Urigen Pharmaceuticals Announces a Partial Debt Restructuring
	Business Wire (Thu, Oct 29)

•	URIGEN PHARMACEUTICALS, INC. Files SEC form 8-K, Unregistered Sale of Equity Securities
	EDGAR Online (Wed, Oct 28)

•	Urigen Overview of IC/Painful Bladder Syndrome for IC Awareness Week
	Business Wire (Tue, Oct 27)

•	URIGEN PHARMACEUTICALS, INC. Financials
	EDGAR Online Financials (Tue, Sep 29)

•	URIGEN PHARMACEUTICALS, INC. Files SEC form 10-K, Annual Report
	EDGAR Online (Thu, Sep 24)

•	URIGEN PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and
	EDGAR Online (Wed, Aug 26)

•	URIGEN PHARMACEUTICALS, INC. Files SEC form 8-K, Unregistered Sale of Equity Securities, Financial Statements and Exh
	EDGAR Online (Thu, Aug 20)

More Headlines for URGP.OB...

ANALYST

EPS Est (next year) (Dec-69) :	N/A
EPS Est (in 2 years) (Dec-69) :	N/A
Avg Rec (current)*:	1.0
PEG Ratio:	N/A

* (Strong Buy) 1.0 - 5.0 (Strong Sell)

Analyst Opinion - Estimates

BUSINESS SUMMARY

Urigen Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes therapeutic products for urological disorders. Its products include URG101, which completed Phase II clinical trial for the treatment of painful bladder ...

Full Company Profile

Add to Portfolio

Email to a Friend

•